Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3

In LUX-Lung 3, afatinib significantly improved progression-free survival (PFS) versus cisplatin/pemetrexed in EGFR mutation-positive lung adenocarcinoma patients and overall survival (OS) in Del19 patients. Preplanned analyses in Japanese patients from LUX-Lung 3 were performed. Patients were random...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Terufumi, Yoshioka, Hiroshige, Okamoto, Isamu, Yokoyama, Akira, Hida, Toyoaki, Seto, Takashi, Kiura, Katsuyuki, Massey, Dan, Seki, Yoko, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582990/
https://www.ncbi.nlm.nih.gov/pubmed/26094656
http://dx.doi.org/10.1111/cas.12723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582990/
https://www.ncbi.nlm.nih.gov/pubmed/26094656
http://dx.doi.org/10.1111/cas.12723

Ejemplares similares